source
- Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027Context Therapeutics has stopped development of the bispecific T-cell engager CT-95, freeing up cash to extend its runway beyond readouts on its two priority clinical programs.Fierce Biotech · 17h ago↗ source
- Actimed gets back rights to wasting disease drug, ending $126M deal with FaradayActimed Therapeutics has brought the full rights to its wasting disease drug back in-house, securing “strategic control” over the asset but losing out on a shot at over $120 million in biobucks.Fierce Biotech · 18h ago↗ source
- Braveheart charges past expectations with $382.5M IPO to fund cardio drug from HengruiBraveheart Bio has overcome its own IPO expectations, rallying $382.5 million in an upsized listing to fund its cardiovascular ambitions.